Moderna, Inc. $MRNA Stock Holdings Increased by Retirement Systems of Alabama

Retirement Systems of Alabama lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 5.0% during the third quarter, Holdings Channel reports. The institutional investor owned 77,862 shares of the company’s stock after acquiring an additional 3,678 shares during the quarter. Retirement Systems of Alabama’s holdings in Moderna were worth $14,994,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Moderna in the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP bought a new stake in Moderna during the second quarter worth about $564,272,000. Wellington Management Group LLP boosted its stake in Moderna by 4.4% during the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after acquiring an additional 103,977 shares in the last quarter. First Trust Advisors LP boosted its stake in Moderna by 59.3% during the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after acquiring an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. purchased a new stake in Moderna in the second quarter worth about $161,642,545. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MRNA. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Bank of America lifted their target price on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, October 9th. The Goldman Sachs Group boosted their price target on Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a research report on Monday. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Finally, Deutsche Bank initiated coverage on Moderna in a research report on Friday, August 28th. They set a “hold” rating and a $125.00 price objective for the company. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $113.75.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is owned by corporate insiders.

Moderna Price Performance

MRNA opened at $231.35 on Friday. The stock has a 50-day moving average price of $200.18 and a 200-day moving average price of $95.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The firm has a market cap of $93.61 billion, a PE ratio of -32.58 and a beta of 1.16. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $280.80.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same quarter in the previous year, the business posted ($0.51) EPS. Moderna’s revenue was up 29.2% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -5.34 earnings per share for the current fiscal year.

Key Headlines Impacting Moderna

These are some of the MRNA headlines that stood out recently:

• Positive Sentiment: Moderna raised its 2026 revenue-growth outlook to 15%–25%, up from its prior forecast of growth of up to 10%. Stronger overseas COVID-19 sales and the improved outlook provide near-term support. Article: Moderna Raises 2026 Revenue Growth Forecast
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending
• Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.